The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis.
Sixteen women with multiple sclerosis who complained of nocturia completed a double-blind cross-over trial of Desmopressin (DDAVP) and placebo. Nocturia was reduced from a mean of 2.55 voids to 2.01 with placebo and to 1.28 with Desmopressin (p less than 0.01, for the difference between placebo and Desmopressin). Side effects were minor, and equally distributed between treatment and placebo.
D001127:Arginine Vasopressin / Q000627:therapeutic use*; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications*; D014555:Urination Disorders / Q000188:drug therapy*
D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin